These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 26611270)

  • 1. Country break-out session highlights.
    Fazekas F; Gehring K; Gallo P; Lebrun-Frénay C; Moral E; Myhr KM
    Neurodegener Dis Manag; 2015; 5(6 Suppl):31-7. PubMed ID: 26611270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical case reviews and poster sessions in multiple sclerosis spasticity: main outcomes and highlights.
    Trojano M; Celius EG; Donzé C; Izquierdo G; Patti F; Pöhlau D
    Eur Neurol; 2014; 72 Suppl 1():15-9. PubMed ID: 25278119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Country breakout session highlights.
    Ghezzi A; Filli L; Solaro C; Mekies C; Landete L; Lycke J
    Neurodegener Dis Manag; 2016 Dec; 6(6s):41-44. PubMed ID: 27874497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Break-out session highlights.
    Myhr KM; Mäurer M; Ginés MM; Esposito F; Linker R
    Neurodegener Dis Manag; 2017 Nov; 7(6s):45-49. PubMed ID: 29143586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple sclerosis symptoms and spasticity management: new data.
    Izquierdo G
    Neurodegener Dis Manag; 2017 Nov; 7(6s):7-11. PubMed ID: 29143581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.
    Arroyo González R
    Expert Rev Neurother; 2018 Oct; 18(10):785-791. PubMed ID: 30235965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is new in multiple sclerosis spasticity research? Poster session highlights.
    Ghezzi A
    Neurodegener Dis Manag; 2016 Dec; 6(6s):45-47. PubMed ID: 27874498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the management of MS symptoms: recently proposed clinical management algorithms.
    Vermersch P
    Neurodegener Dis Manag; 2015; 5(6 Suppl):23-6. PubMed ID: 26611268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is new in MS spasticity research? Poster session highlights.
    Kappos L; Fazekas F
    Neurodegener Dis Manag; 2015; 5(6 Suppl):27-30. PubMed ID: 26611269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the management of MS symptoms: real-life evidence.
    Trojano M
    Neurodegener Dis Manag; 2015; 5(6 Suppl):19-21. PubMed ID: 26611267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms.
    Trojano M
    Eur Neurol; 2016; 75 Suppl 1():4-8. PubMed ID: 26901343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.
    Koehler J; Feneberg W; Meier M; Pöllmann W
    Int J Neurosci; 2014 Sep; 124(9):652-6. PubMed ID: 24392812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the management of multiple sclerosis symptoms: pathophysiology and assessment of spasticity in multiple sclerosis.
    Tintoré M
    Neurodegener Dis Manag; 2015; 5(6 Suppl):15-7. PubMed ID: 26611266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.
    Pozzilli C
    Expert Rev Neurother; 2013 Dec; 13(12 Suppl):49-54. PubMed ID: 24289844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the management of multiple sclerosis spasticity: recent clinical trials.
    Fernández O
    Eur Neurol; 2014; 72 Suppl 1():9-11. PubMed ID: 25278117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study.
    Mallada Frechín J
    Neurodegener Dis Manag; 2018 Jun; 8(3):151-159. PubMed ID: 29851356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines.
    Gold R; Oreja-Guevara C
    Expert Rev Neurother; 2013 Dec; 13(12 Suppl):55-9. PubMed ID: 24289845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health Authorities Data Collection of THC:CBD Oromucosal Spray (L'Agenzia Italiana del Farmaco Web Registry): Figures after 1.5 Years.
    Patti F
    Eur Neurol; 2016; 75 Suppl 1():9-12. PubMed ID: 26901344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. THC:CBD in Daily Practice: Available Data from UK, Germany and Spain.
    Fernández Ó
    Eur Neurol; 2016; 75 Suppl 1():1-3. PubMed ID: 26901342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. THC:CBD spray and MS spasticity symptoms: data from latest studies.
    Rekand T
    Eur Neurol; 2014; 71 Suppl 1():4-9. PubMed ID: 24457846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.